Avalyn Pharma files for IPO

Avalyn Pharma has quietly joined the 2026 biotech line for the public market by confidentially submitting a draft Form S-1 to the United States Securities and Exchange Commission on February 6, 2026, with Lyn Baranowski listed as chief executive and Boston as its principal office. (sec.gov) That kind of filing is the paperwork a private company uses to start an initial public offering, which is the process of selling shares to public investors for the first time. (sec.gov) Avalyn is not a platform company chasing ten diseases at once. Its website says it is a clinical-stage company focused on rare lung diseases, with inhaled drug programs aimed at pulmonary fibrosis and related interstitial lung diseases. (avalynpharma.com) Pulmonary fibrosis is scarring in the lungs, so each breath works like air moving through a stiff sponge instead of a soft one. Avalyn’s bet is that inhaled medicine can put more drug into lung tissue and avoid some of the body-wide side effects that come with swallowing pills. (avalynpharma.com) Its two main programs are AP01, an inhaled version of pirfenidone, and AP02, an inhaled version of nintedanib. Those are built from two drugs already used in fibrosis, but Avalyn is trying to change where the drug lands in the body by delivering it through a nebulizer. (avalynpharma.com) The company’s own materials say AP01 is already in a Phase 2b study for progressive pulmonary fibrosis, while AP02 has moved into Phase 2 development for idiopathic pulmonary fibrosis after Phase 1 work. That gives investors something more concrete than a lab idea and less proven than a late-stage product. (avalynpharma.com 1) (avalynpharma.com 2) Avalyn also came into this filing with fresh private money. In July 2025, BiotechTV reported that the company had raised a $100 million Series D round, and Baranowski said the inhaled approach is designed to let patients take higher doses than oral therapy can comfortably support. (biotechtv.com) That sequence matters. A company that can raise a nine-figure private round in 2025 and then move toward an initial public offering in 2026 usually goes public to fund the expensive middle stretch of drug development, where Phase 2 studies, manufacturing scale-up, and regulatory prep start burning cash fast. (biotechtv.com) (sec.gov) It also says something about what the market is willing to buy right now. Investors have been selective, and Avalyn fits the pattern they still fund: a company with named drug candidates, human clinical data, and a disease area where existing treatments still leave room for better dosing and tolerability. (avalynpharma.com 1) (avalynpharma.com 2) If Avalyn completes the offering, the ripple will not stop at its cap table. Contract development and manufacturing organizations, which are the outside firms that make trial material and assemble regulatory packages, often see more work when a biotech gets public-market cash and pushes harder toward clinical milestones. (sec.gov)